Can Omeros Corporation (OMER)’s Tomorrow Be Different? The Stock Increases Again

April 26, 2018 - By Hazel Jackson

Omeros Corporation (NASDAQ:OMER) Logo

Investors sentiment decreased to 1.3 in Q4 2017. Its down 1.56, from 2.86 in 2017Q3. It is negative, as 14 investors sold Omeros Corporation shares while 29 reduced holdings. 31 funds opened positions while 25 raised stakes. 21.94 million shares or 0.43% less from 22.04 million shares in 2017Q3 were reported.
State Street has 0% invested in Omeros Corporation (NASDAQ:OMER). Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,779 shares. Chicago Equity Ptnrs Ltd Co holds 195,120 shares or 0.12% of its portfolio. State Of Wisconsin Invest Board holds 44,600 shares or 0% of its portfolio. The Massachusetts-based Rhumbline Advisers has invested 0% in Omeros Corporation (NASDAQ:OMER). California State Teachers Retirement stated it has 71,709 shares. 109,137 were accumulated by Mutual Of America Mngmt Limited Liability. Raymond James & Associates has invested 0% in Omeros Corporation (NASDAQ:OMER). Tiaa Cref Mngmt Limited Company reported 103,639 shares. Pnc Fincl Services Gp Incorporated holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 48 shares. Northwestern Mutual Wealth Mngmt Company, Wisconsin-based fund reported 63 shares. Davenport & Ltd Company accumulated 79,400 shares or 0.02% of the stock. Barclays Public Limited accumulated 8,647 shares. Mcf Limited Liability holds 1,814 shares. Principal Financial owns 26,710 shares or 0% of their US portfolio.

Since January 3, 2018, it had 0 insider buys, and 2 insider sales for $1.36 million activity. On Wednesday, January 3 Kelbon Marcia S. sold $1.34 million worth of Omeros Corporation (NASDAQ:OMER) or 62,528 shares.

The stock of Omeros Corporation (NASDAQ:OMER) is a huge mover today! The stock increased 9.97% or $1.3676 during the last trading session, reaching $15.0876. About 1.92M shares traded or 32.58% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 3.39% since April 26, 2017 and is downtrending. It has underperformed by 14.94% the S&P500.
The move comes after 6 months positive chart setup for the $728.52M company. It was reported on Apr, 26 by Barchart.com. We have $16.29 PT which if reached, will make NASDAQ:OMER worth $58.28M more.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on May, 9. They expect $-0.53 earnings per share, down 120.83 % or $0.29 from last year’s $-0.24 per share. After $-0.25 actual earnings per share reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 112.00 % negative EPS growth.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 6 analysts covering Omeros (NASDAQ:OMER), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Omeros had 15 analyst reports since November 2, 2017 according to SRatingsIntel. On Wednesday, November 29 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was maintained on Thursday, March 22 by Maxim Group. As per Tuesday, November 28, the company rating was maintained by Wedbush. The rating was maintained by H.C. Wainwright on Thursday, January 4 with “Buy”. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Monday, March 5 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, January 23 report. Wedbush downgraded the stock to “Neutral” rating in Friday, March 23 report. The stock has “Hold” rating by Needham on Friday, March 2. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) rating on Friday, March 23. H.C. Wainwright has “Buy” rating and $3400 target. The stock has “Buy” rating by H.C. Wainwright on Thursday, April 19.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $728.52 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.